AIM - AIM ImmunoTech Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
1.0500
-0.0500 (-4.55%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.1000
Open1.0800
Bid0.8820 x 1800
Ask1.0500 x 2200
Day's Range1.0000 - 1.0800
52 Week Range0.0930 - 14.9600
Volume2,266,406
Avg. Volume2,418,730
Market Cap8.677M
Beta (5Y Monthly)0.69
PE Ratio (TTM)N/A
EPS (TTM)-5.8730
Earnings DateOct 06, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.58
  • ACCESSWIRE

    AIM ImmunoTech Issues Stockholder Update on the Potential Role of Ampligen for Use Against the Wuhan Coronavirus Epidemic

    OCALA, FL / ACCESSWIRE / February 18, 2020 / AIM ImmunoTech (NYSE American:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple types of cancers, today provided its stockholders with an update on its efforts to develop Ampligen as a protective therapeutic and a vaccine in the new coronavirus epidemic. Ampligen, the company's flagship drug, has a commercial approval in Argentina, early-access therapeutic approval in the Netherlands, and is in numerous FDA-authorized clinical trials in the United States. This letter provides a detailed scientific basis for why the company is moving forward in the important and volatile Wuhan coronavirus space.

  • ACCESSWIRE

    AIM ImmunoTech’s CEO to Appear Live Today on FOX Business Network’s The Claman Countdown and Cheddar’s Opening Bell to Discuss the Potential Role of Ampligen(R) for Use Against the Wuhan 2019 Novel Coronavirus

    OCALA, FL / ACCESSWIRE / February 12, 2020 / AIM ImmunoTech Inc. (NYSE American:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple types of cancers, today announced that its Chief Executive Officer, Thomas K. Equels, will appear live today as a guest on FOX Business Network's The Claman Coutdown and Cheddar's Opening Bell. Mr. Equels is scheduled to appear on Cheddar's Opening Bell with hosts Hope King and Nora Ali at 10:20 AM ET.

  • GlobeNewswire

    AIM ImmunoTech Files Three Provisional Patent Applications Surrounding Ampligen® for Use Against the SARS-like Wuhan 2019 Novel Coronavirus

    AIM ImmunoTech Inc. (NYSE American: AIM) today announced the filing of three provisional patent applications related to its drug candidate Ampligen in the company’s efforts toward joining the global health community in the fight against the deadly Wuhan coronavirus that has so far infected approximately 40,000 people and killed almost one thousand, primarily in China. After a 2002 SARS outbreak in the Guangdong province of southern China caused more than 8,000 cases and more than 800 deaths, the United States’ National Institutes of Health contracted studies to evaluate potential treatments for SARS.

  • ACCESSWIRE

    AIM ImmunoTech Files Three Provisional Patent Applications Surrounding Ampligen(R) for Use Against the SARS-like Wuhan 2019 Novel Coronavirus

    OCALA, FL / ACCESSWIRE / February 11, 2020 / AIM ImmunoTech Inc. (NYSE American:AIM) today announced the filing of three provisional patent applications related to its drug candidate Ampligen in the company's efforts toward joining the global health community in the fight against the deadly Wuhan coronavirus that has so far infected approximately 40,000 people and killed almost one thousand, primarily in China. After a 2002 SARS outbreak in the Guangdong province of southern China caused more than 8,000 cases and more than 800 deaths, the United States' National Institutes of Health contracted studies to evaluate potential treatments for SARS.

  • ACCESSWIRE

    AIM ImmunoTech Announces Completion of Third-Party Clinical Trial Using Ampligen in Combination with Other Therapies as Adjuvant Treatment of Peritoneal Surface Malignancies

    OCALA, FL / ACCESSWIRE / February 5, 2020 / AIM ImmunoTech Inc. (NYSE American: AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, today announced posting by the University of Pittsburgh Medical Center (UPMC) on January 28, 2020 via ClinicalTrials.gov of completion of an independent, third-party clinical trial to evaluate the safety and activity of a triple combination (chemokine modulatory regimen or CKM) of celecoxib, interferon alfa (IFN), and Ampligen (rintatolimod), given with a dendritic cell (DC) vaccine, as a potential treatment for metastatic peritoneal surface malignancies after standard of care surgery. The principal investigator of the trial was David L. Bartlett, MD, an internationally recognized cancer researcher at UPMC, in collaboration with the National Cancer Institute.

  • Read This Before Selling AIM ImmunoTech Inc. (NYSEMKT:AIM) Shares
    Simply Wall St.

    Read This Before Selling AIM ImmunoTech Inc. (NYSEMKT:AIM) Shares

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...

  • ACCESSWIRE

    AIM ImmunoTech to Present at the Investor Summit in Philadelphia

    OCALA, FL / ACCESSWIRE / December 11, 2019 / AIM ImmunoTech Inc. (NYSE American:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, ...

  • ACCESSWIRE

    AIM ImmunoTech Issues Stockholder Update and Details Its Expectations for 2020

    OCALA, FL / ACCESSWIRE / December 4, 2019 / AIM ImmunoTech (NYSE American:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases - such as severe chronic fatigue syndrome (CFS) - today provided its stockholders with an update on the first three quarters of 2019 and detailed expected upcoming milestones in clinical studies using its drug Ampligen. This has been a transformational year for AIM ImmunoTech. Several more clinical trials are slated for 2020.

  • ACCESSWIRE

    CORRECTION: AIM ImmunoTech Provides Business Update for the Third Quarter of 2019

    The company had cash, cash equivalents and marketable securities of $1,825,000 as of December 31, 2018, not December 31, 2019. OCALA, FL / ACCESSWIRE / November 15, 2019 / AIM ImmunoTech (NYSE American:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases - such as severe chronic fatigue syndrome (CFS) - provides a business update for the third quarter ended September 30, 2019, and has filed its form 10-Q with the U.S. Securities and Exchange Commission, which is available on the Company's website. Announced the U.S. Department of Defense's (DOD) $6.42M "Breakthrough Award" to Roswell Park Comprehensive Cancer Center to fund a clinical trial to study Ampligen as a potential synergistic agent in combination with several other immunotherapies, such as pembrolizumab, in the treatment of brain-metastatic breast cancer.

  • ACCESSWIRE

    AIM ImmunoTech Provides Business Update for the Third Quarter of 2019

    OCALA, FL / ACCESSWIRE / November 15, 2019 / AIM ImmunoTech (NYSE American:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases - such as severe chronic fatigue syndrome (CFS) - provides a business update for the third quarter ended September 30, 2019, and has filed its form 10-Q with the U.S. Securities and Exchange Commission, which is available on the Company's website. Announced the U.S. Department of Defense's (DOD) $6.42M "Breakthrough Award" to Roswell Park Comprehensive Cancer Center to fund a clinical trial to study Ampligen as a potential synergistic agent in combination with several other immunotherapies, such as pembrolizumab, in the treatment of brain-metastatic breast cancer.

  • ACCESSWIRE

    AIM ImmunoTech to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference

    OCALA, FL / ACCESSWIRE / October 23, 2019 / AIM ImmunoTech Inc. (NYSE American:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, ...

  • ACCESSWIRE

    AIM ImmunoTech Provides Comprehensive Clinical Trials Update With Major Inflection Points Identified

    Well Capitalized to Complete Current Ampligen Clinical Trials Following $10M in Capital Raises Plus $15M Recently Awarded by DOD to Roswell Park and Moffitt for Ampligen-Related Breast Cancer Trials OCALA, ...

  • ACCESSWIRE

    AIM ImmunoTech, Inc. Announces Pricing of $8 Million Public Offering

    OCALA, FL / ACCESSWIRE / September 25, 2019 / AIM ImmunoTech, Inc. (NYSE American:AIM) (the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, today announced the pricing of an underwritten public offering of (i) 1,740,550 shares of common stock together with common stock warrants (the "common warrants") to purchase 1,740,550 shares of common stock and (ii) 7,148,310 pre-funded warrants, with each pre-funded warrant exercisable for one share of common stock, together with common warrants to purchase 7,148,310 shares of common stock. The shares of common stock (or pre-funded warrants, as applicable) and accompanying common warrants are being sold together at a combined public offering price of $0.90 per share.

  • ACCESSWIRE

    AIM ImmunoTech Inc. Announces a Second DoD Award, This One of $8.3 Million, to Fund Phase 2 Clinical Trial to Study Ampligen as Part of a New Treatment for Brain-Metastatic Breast Cancer at the Moffitt Cancer Center

    OCALA, FL / ACCESSWIRE / September 24, 2019 / AIM ImmunoTech (NYSE American:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, today announces the U.S. Department of Defense (DoD) has granted $8.32 million in funding in another "Breakthrough Award". This award is to Moffitt Cancer Center for a Phase 2 clinical study of a combination of therapies, including the Company's drug Ampligen, in patients with brain-metastatic breast cancer (BMBC).

  • ACCESSWIRE

    AIM ImmunoTech’s Ampligen Receives Clearance from FDA for Exportation to Argentina for the Treatment of Severe Chronic Fatigue Syndrome

    OCALA, FL / ACCESSWIRE / September 24, 2019 / AIM ImmunoTech (NYSE American:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases - such as severe chronic fatigue syndrome (CFS) - has received clearance to export to Argentina from the U.S. Food and Drug Administration (FDA) its flagship drug Ampligen. In 2016, the company announced the approval of its New Drug Application (NDA) from Argentina's Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica (ANMAT) for the commercial sale of Ampligen for the treatment of CFS. The FDA requires certain regulations be met in order to export a drug manufactured in the United States to a foreign country.

  • Benzinga

    AIM ImmunoTech Shares Spike Up 90% After $6.42M 'Breakthrough Award'

    Shares of thinly-traded microcap AIM ImmunoTech Inc. (NYSE: AIM ) are trading sharply higher after the company announced the Department of Defense granted a four-year, $6.42 million "Breakthrough ...

  • ACCESSWIRE

    AIM ImmunoTech Inc. Announces the U.S. Department of Defense’s Award of $6.42M to Roswell Park Comprehensive Cancer Center to Study Ampligen as Part of a New Treatment of Brain-Metastatic Breast Cancer

    OCALA, FL / ACCESSWIRE / September 19, 2019 / AIM ImmunoTech Inc. (NYSE American:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases - such as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) - today announced that the U.S. Department of Defense (DOD) has granted a four-year, $6.42 million "Breakthrough Award" to Roswell Park Comprehensive Cancer Center (Roswell Park) for a clinical study of a combination of therapies, including the company's drug Ampligen, in patients with brain-metastatic breast cancer (BMBC). Drs. Shipra Gandhi and Pawel Kalinski of Roswell Park Comprehensive Cancer Center will lead a Department of Defense-funded clinical trial assessing a three-pronged immunotherapy strategy for brain-metastatic breast cancer.

  • ACCESSWIRE

    AIM ImmunoTech Names Ellen Lintal as New Chief Financial Officer

    OCALA, FL / ACCESSWIRE / September 16, 2019 / AIM ImmunoTech Inc. (NYSE American:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases - such as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) - today named Ellen Lintal as its new Chief Financial Officer. The Board of Directors unanimously approved Lintal for the senior leadership position. Lintal joined the company - then named Hemispherx Biopharma Inc. - in 2018 as Vice President of Finance & Control, before being promoted to Chief Accounting Officer earlier this year.

  • ACCESSWIRE

    AIM ImmunoTech Inc. to Present at the Fall Investor Summit on September 16th-17th in New York City

    OCALA, FL / ACCESSWIRE / September 13, 2019 / AIM ImmunoTech Inc. (NYSE American:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers ...

  • ACCESSWIRE

    AIM ImmunoTech Announces Progress Toward Opening of Breast Cancer Study at Roswell Park Comprehensive Cancer Center

    OCALA, FL / ACCESSWIRE / September 10, 2019 / AIM ImmunoTech Inc., (NYSE American:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers ...

  • ACCESSWIRE

    AIM ImmunoTech Inc. Announces its Name Change is Complete, Its New Website is Up and the Company Now Trades as Ticker Symbol 'AIM'

    OCALA, FL / ACCESSWIRE / September 9, 2019 / AIM ImmunoTech Inc. (NYSE American:AIM) announced today that its name change is now complete, with the company’s new website of www.aimimmuno.com and trading on the NYSE American as ‘AIM.’ The immuno-tech company, which is focused on the research and development of immunological agents to treat multiple types of cancers and immune-deficiency diseases -such as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) - had previously been Hemispherx Biopharma, Inc. "Amplified Immunological Modulation - or 'AIM' - is what our company is all about. In addition, the company’s Twitter handle is now @AIMImmuno.

  • ACCESSWIRE

    AIM ImmunoTech to Present at the 21st Annual Rodman & Renshaw Global Investment Conference in New York City on September 10th

    OCALA, FL / ACCESSWIRE / September 6, 2019 / AIM ImmunoTech Inc. (NYSE American:AIM), an immuno-tech company focused on the research and development of immunological agents to treat multiple types of cancers ...